Suchergebnisse - "Specchia, Giorgina"

PubPharm (14)

1

Additional chromosomal abnormalities in Philadelphia-positive clone : adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

enthalten in: Blood | 2012

von Luatti, S. | Castagnetti, F. | Marzocchi, G. | +24

ErratumIn: Blood. 2013 Jun 27;121(26):5259 Cambrin, Rege [corrected to Rege-Cambrin, Giovanna]

2

Variant Philadelphia translocations : molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

enthalten in: Blood | 2011

von Marzocchi, G. | Castagnetti, F. | Luatti, S. | +23

CommentIn: Blood. 2011 Jun 23;117(25):6741-2. - PMID 21700778

3

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

enthalten in: American journal of hematology | 2010

von Visani, G. | Breccia, M. | Gozzini, A. | +12

4

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone : a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

enthalten in: Haematologica | 2010

von Palandri, F. | Castagnetti, F. | Iacobucci, I. | +17

5

Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements

enthalten in: Molecular cancer | 2010

von Albano, F. | Anelli, L. | Zagaria, A. | +7

6

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia : a European LeukemiaNet Study

enthalten in: Blood | 2009

von Baccarani, M. | Rosti, G. | Castagnetti, F. | +22

7

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase : a phase 2 trial of the GIMEMA CML Working Party

enthalten in: Blood | 2009

von Castagnetti, F. | Palandri, F. | Amabile, M. | +54

8

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg : the GIMEMA CML Working Party experience after a 7-year follow-up

enthalten in: Haematologica | 2009

von Palandri, F. | Castagnetti, F. | Alimena, G. | +16

CommentIn: Haematologica. 2009 May;94(5):743-4. - PMID 19407320

9

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib : long-term results

enthalten in: Leukemia & lymphoma | 2009

von Palandri, F. | Testoni, N. | Luatti, S. | +11

10

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg : outcome of the patients alive after a 6-year follow-up

enthalten in: Haematologica | 2008

von Palandri, F. | Castagnetti, F. | Testoni, N. | +20

CommentIn: Haematologica. 2008 Dec;93(12):1765-9. - PMID 19050065